Bevacizumab抑制高转移性人肝癌原位移植瘤的血管形成  

Anti-angiogenic Effectiveness of LCI-D20 Hepatocellular Carcinoma by Bevacizumab

作　　者：陈方国[1] 陈漪[2] 于观贞[1] 薛琼[2] 侯亮[1] 郭子姮[1] 王杰军[1] 

机构地区：[1]上海第二军医大学附属长征医院肿瘤科,上海200070 [2]复旦大学附属中山医院肝癌研究所,上海200032

出　　处：《中国临床医学》2006年第6期940-941,共2页Chinese Journal of Clinical Medicine

摘　　要：目的：探讨Bevacizumab对人高转移肝癌模型ICI—D20血管形成的抑制作用。方法：分别采用空白对照及Bevaci—zumab治疗LCI—D20,用药28d后处死裸鼠,测量肿瘤质量,检测肿瘤组织微血管密度。结果：对照组肿瘤负荷平均为2．0 g；MVD(microvascular density,微血管密度)平均39．6个/HP；治疗组平均肿瘤负荷为0．1g及平均MVD为4．9个/HP,与对照组比较有显著差异(P＜0．05)。结论：Bevacizumab有抑制肝癌血管形成及肿瘤生长的活性。Objective：To investigate the role of Bevacizumab on angiogenesis and in the treatment of hepatocellular carcinoma in animal model. Methods：Nude mice bearing orthotopic xenografty highly metastatic human HCC（LCI-D20） were randomly devided into two groups： Control group（A） and Bevacizumab group（B）. At the 28 days after the treatment with normal saline and Bevacizumab, tumors in LCI-D20 mice were moved out. Tumor quality was measured and microvessel density（MVD） was used to evaluate angiogenesis in tumor. Results： The mean tumor quality was 2. 0g, 0. lg in A, B respectively and the mean MVD was 39. 6, 4. 9 in A, B group respectively. Bevacizumab significantly reduced MVD of tumor vessels and tumor quality compared with the control group （P〈0. 05）. Conclusion..Bevacizumab can effectively inhibit angiogenesis and tumor growth of LCI-D20 HCC in nude mice.

关 键 词：肝癌 血管形成 血管形成抑制剂 BEVACIZUMAB 

分 类 号：R735.7[医药卫生—肿瘤]